SES
EAGLE-1 consortium lead SES announces a new key partner, TESAT, responsible for developing and integrating the Quantum Key Distribution (QKD) payload for the EAGLE-1 satellite. The SES and TESAT partnership is aimed at achieving the next key milestone in building and implementing Europe’s pioneering quantum secure communications initiative EAGLE-1. Supported by the European Space Agency (ESA) and the European Commission, EAGLE-1 is a quantum key system integrating both space and ground segments that will deliver secure transmission of encryption keys across geographically dispersed areas and connect EU’s national quantum communications infrastructures for truly sovereign networks.
Consortium member and Europe’s leading laser communication technology company TESAT will manufacture the QKD payload comprising the Scalable Optical Terminal SCOT80 to establish a secure optical link from space to ground, as well as the QKD module of the satellite.
The technology integrated into the EAGLE-1 system’s payload will include built-in redundancy and is specifically designed to be associated with the satellite communications and data transmission for such areas as government, telco operators, cloud providers and banking, to add guaranteed security of the cryptographic applications.
“EAGLE-1 is a project that will benefit the whole of Europe, and being able to work with the leading technology players in the market to co-develop it and together shape this innovative secure technology is a privilege to SES,” said Ruy Pinto, Chief technology Officer of SES. “The addition of the secure optical links and the actual QKD module brings us closer to implementation, testing and further scaling the technology, that can ultimately serve millions of users. This elevates secure communications to an entirely new level, supporting development of reliable pan-European quantum communications infrastructures.”
“We are delighted to be selected as payload prime by SES and looking forward to bring our expertise in integrating secure technologies, and a track record of almost 80,000 executed optical satellite links for the benefit of this highly-important and timely European project,” said Thomas Reinartz, CEO of TESAT. “The EAGLE-1 system allows for achieving synergies together with leading industry partners, SMEs and institutes, reducing time to service and to market for the quantum secure technologies and its future key users, such as governments and institutions, or banking sector. Together with our partners, we are looking forward to strengthen European collaboration at all levels, including SMEs and institutions and contributing to European sovereignty in space.”
About EAGLE-1
The EAGLE-1 project comprising satellite and ground infrastructure is developed by SES and its consortium of 20 European partners, and is co-funded by the ESA contribution of Germany, Luxembourg, Austria, Italy, the Netherlands, Switzerland, Belgium, and the Czech Republic under ARTES, as well as the European Commission through Horizon Europe.
Once launched in 2024, the EAGLE-1 satellite will complete three years of in-orbit mission. During the operational phase, the satellite will allow European Union governments and institutions as well as critical business sectors early access to long-distance QKD that would path the way towards an EU constellation enabling ultra-secure data transmissions.
Learn more about EAGLE-1 and SES-led consortium of European partners here.
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over ~8,200 channels and has an unparalleled reach of 369 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
About TESAT
TESAT is a world-leading manufacturer for satellite equipment. More than 1,100 employees, based in Backnang, Germany, develop, manufacture and distribute systems and equipment for satellite communications every day. The product range spans from the smallest space-specific components to modules, entire assemblies or payloads. As the world’s leading provider of in-orbit-verified optical communication terminals for data transmission via laser, TESAT has a focus on commercial and institutional space programs. Thanks to the deep understanding of the market needs, customer focus and technological innovation, TESAT offers products that contribute to sustainable development and security, for the people, for a better world. More information at www.tesat.de.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510006052/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom